Canada Approves First Prescription Melatonin for Sleep Support in Autistic Children

Health Canada has approved the first prescription melatonin formulation specifically indicated to support sleep in autistic children and adolescents, as well as those with Smith-Magenis syndrome (SMS), a genetic condition involving circadian rhythm disruptions. The extended-release tablets, branded as SLENYTO®, were authorized in late March based on pharmacokinetic data bridging existing research on melatonin supplements in these populations (PR Newswire).

Sleep Support Considerations

Many autistic individuals experience differences in sleep initiation and maintenance, which can create barriers to daily functioning. Clinical studies suggest that short-term melatonin use (under 12 weeks) may help some children fall asleep faster, though individual responses vary. A 2020 Neurology guideline reviewing generic melatonin noted modest improvements, while research in Frontiers in Psychiatry highlights the complexity of circadian rhythm differences in autism.

Clinical studies suggest that short-term melatonin use (under 12 weeks) may help some children fall asleep faster, though individual responses vary.

Evidence and Open Questions

The approval draws on existing safety data, but dedicated long-term studies in autistic children remain limited. 'We have clear short-term data but need more research on prolonged use,' noted a Science Media Centre España analysis. Parents and clinicians should note that over-the-counter melatonin varies widely in dosage accuracy, making prescription formulations like SLENYTO® preferable when melatonin is deemed appropriate (Child Mind Institute).

Neurodiversity-affirming sleep strategies—such as adjusting sensory environments, maintaining consistent routines, and collaborative problem-solving—should be considered alongside any pharmacological approach. The Simons Sleep Project is building open-source tools to better understand sleep patterns across neurotypes, though its current work doesn't specifically address melatonin safety.